189 related articles for article (PubMed ID: 30151740)
21. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia.
Choudhury A; Gajewski JL; Liang JC; Popat U; Claxton DF; Kliche KO; Andreeff M; Champlin RE
Blood; 1997 Feb; 89(4):1133-42. PubMed ID: 9028934
[TBL] [Abstract][Full Text] [Related]
22. Effect of Tyrosin Kinase Inhibitors on NK Cell and ILC3 Development and Function.
Damele L; Montaldo E; Moretta L; Vitale C; Mingari MC
Front Immunol; 2018; 9():2433. PubMed ID: 30405627
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai T; Nakaseko C; Nishiwaki K; Yoshida C; Ohashi K; Takezako N; Takano H; Kouzai Y; Murase T; Matsue K; Morita S; Sakamoto J; Wakita H; Sakamaki H; Inokuchi K;
Cancer Sci; 2018 Jan; 109(1):182-192. PubMed ID: 29058817
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.
Guarini A; Breccia M; Montefusco E; Petti MC; Zepparoni A; Vitale A; Foa R
Br J Haematol; 2001 Apr; 113(1):136-42. PubMed ID: 11328293
[TBL] [Abstract][Full Text] [Related]
25. Role of T-cell antigens in the cytolytic activities of large granular lymphocytes (LGLs) in patients with LGL lymphocytosis.
Oshimi K; Oshimi Y; Akahoshi M; Kobayashi Y; Hirai H; Takaku F; Hattori M; Asano S; Kodo H; Nishinarita S
Blood; 1988 Feb; 71(2):473-9. PubMed ID: 2447984
[TBL] [Abstract][Full Text] [Related]
26. Comparison of primary human cytotoxic T-cell and natural killer cell responses reveal similar molecular requirements for lytic granule exocytosis but differences in cytokine production.
Chiang SC; Theorell J; Entesarian M; Meeths M; Mastafa M; Al-Herz W; Frisk P; Gilmour KC; Ifversen M; Langenskiöld C; Machaczka M; Naqvi A; Payne J; Perez-Martinez A; Sabel M; Unal E; Unal S; Winiarski J; Nordenskjöld M; Ljunggren HG; Henter JI; Bryceson YT
Blood; 2013 Feb; 121(8):1345-56. PubMed ID: 23287865
[TBL] [Abstract][Full Text] [Related]
27. Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph
Ishiyama K; Kitawaki T; Sugimoto N; Sozu T; Anzai N; Okada M; Nohgawa M; Hatanaka K; Arima N; Ishikawa T; Tabata S; Onaka T; Oka S; Nakabo Y; Amakawa R; Matsui M; Moriguchi T; Takaori-Kondo A; Kadowaki N
Leukemia; 2017 Jan; 31(1):203-212. PubMed ID: 27349810
[TBL] [Abstract][Full Text] [Related]
28. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Najima Y; Yoshida C; Iriyama N; Fujisawa S; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Leuk Res; 2018 Mar; 66():66-72. PubMed ID: 29407585
[TBL] [Abstract][Full Text] [Related]
29. Polyfunctional KLRG-1
Ramello MC; Núñez NG; Tosello Boari J; Bossio SN; Canale FP; Abrate C; Ponce N; Del Castillo A; Ledesma M; Viel S; Richer W; Sedlik C; Tiraboschi C; Muñoz M; Compagno D; Gruppi A; Acosta Rodríguez EV; Piaggio E; Montes CL
Front Immunol; 2021; 12():713132. PubMed ID: 34386013
[TBL] [Abstract][Full Text] [Related]
30. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Powers JJ; Dubovsky JA; Epling-Burnette PK; Moscinski L; Zhang L; Mustjoki S; Sotomayor EM; Pinilla-Ibarz JA
Leuk Lymphoma; 2011 Apr; 52(4):668-79. PubMed ID: 21271862
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
33. Large granular lymphocytosis induced by dasatinib.
Fernandes F; Ramalho R; Barreira R; Silveira M; Bain BJ
Am J Hematol; 2021 Mar; 96(3):395-396. PubMed ID: 32757492
[No Abstract] [Full Text] [Related]
34. Dasatinib-induced spleen contraction leads to transient lymphocytosis.
Marcos-Jiménez A; Carvoeiro DC; Ruef N; Cuesta-Mateos C; Roy-Vallejo E; Gómez-García de Soria V; Laganá C; Del Campo L; Zubiaur P; Villapalos-García G; Abad-Santos F; Stein JV; Muñoz-Calleja C
Blood Adv; 2023 Jun; 7(11):2418-2430. PubMed ID: 36583674
[TBL] [Abstract][Full Text] [Related]
35. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
36. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
[TBL] [Abstract][Full Text] [Related]
37. Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from CML patients.
Li Y; Geng S; Du X; Chen S; Yang L; Wu X; Li B; Schmidt CA; Przybylski GK
Hematology; 2011 Jan; 16(1):43-9. PubMed ID: 21269567
[TBL] [Abstract][Full Text] [Related]
38. Effects of BCR-ABL inhibitors on anti-tumor immunity.
Krusch M; Salih HR
Curr Med Chem; 2011; 18(34):5174-84. PubMed ID: 22087818
[TBL] [Abstract][Full Text] [Related]
39. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Kumagai T; Matsuki E; Inokuchi K; Ohashi K; Shinagawa A; Takeuchi J; Yoshida C; Okamoto S; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Nishiwaki K; Oba K; Sakamoto J; Sakamaki H
Int J Hematol; 2014 Jan; 99(1):41-52. PubMed ID: 24297450
[TBL] [Abstract][Full Text] [Related]
40. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
